Acute Rheumatic Fever: Revised Jones Criteria

Checklist

Episode
Recurrent: reliable past history of ARF or established RHD.
Population
Low-risk: Table 7 footnote *. Not clearly low-risk: moderate to high risk.

Key points

Revised Jones criteria (Table 7)

Table 7, as printed (Gewitz 2015). GAS, group A streptococcal infection.
A. For all patient populations with evidence of preceding GAS infection
Diagnosis: initial ARF2 Major manifestations or 1 major plus 2 minor manifestations
Diagnosis: recurrent ARF2 Major or 1 major and 2 minor or 3 minor
B. Major criteria
Low-risk populations*Moderate- and high-risk populations
Carditis† · Clinical and/or subclinicalCarditis · Clinical and/or subclinical
Arthritis · Polyarthritis onlyArthritis · Monoarthritis or polyarthritis · Polyarthralgia‡
ChoreaChorea
Erythema marginatumErythema marginatum
Subcutaneous nodulesSubcutaneous nodules
C. Minor criteria
Low-risk populations*Moderate- and high-risk populations
PolyarthralgiaMonoarthralgia
Fever (≥38.5°C)Fever (≥38°C)
ESR ≥60 mm in the first hour and/or CRP ≥3.0 mg/dL§ESR ≥30 mm/h and/or CRP ≥3.0 mg/dL§
Prolonged PR interval, after accounting for age variability (unless carditis is a major criterion)Prolonged PR interval, after accounting for age variability (unless carditis is a major criterion)

*Low-risk populations are those with ARF incidence ≤2 per 100 000 school-aged children or all-age rheumatic heart disease prevalence of ≤1 per 1000 population per year.

†Subclinical carditis indicates echocardiographic valvulitis as defined in Table 3.

‡Polyarthralgia should only be considered as a major manifestation in moderate- to high-risk populations after exclusion of other causes. Erythema marginatum and subcutaneous nodules are rarely "stand-alone" major criteria. Additionally, joint manifestations can only be considered in either the major or minor categories but not both in the same patient.

§CRP value must be greater than upper limit of normal for laboratory. Also, because ESR may evolve during the course of ARF, peak ESR values should be used. Our note: 3.0 mg/dL is 30 mg/L.

WHO 2024 Table 1 differs: it prints Monoarthritis and Fever (≥38.5 °C) in the moderate- and high-risk minor column.

What the criteria do not define

Also not defined
  • The size of a significant rise in titer. A rise is better evidence than a single result.
  • Joint counts separating mono from poly.
  • "Reliable past history" and "Rule out all else". Table 6 lists a differential.
  • A child who moved between settings.
  • Whether Table 4 morphology alone meets subclinical carditis. Table 7 names Table 3; the text names Tables 3 and 4.
  • A row or count for chronic, indolent carditis, and whether the Figure's Panel A applies to a recurrence.
  • In a recurrence with established RHD, how to separate current echo findings from baseline ones. Table 4 lists chronic mitral valve changes as "not seen in acute carditis" and aortic changes as "in either acute or chronic carditis", and gives no rule beyond that. The statement says it focuses on the diagnosis of ARF, not the surveillance for and diagnosis of chronic RHD (p. 1808).

Echo findings: subclinical carditis (Table 3)

Table 3, as printed (Gewitz 2015).
Pathological mitral regurgitation (all 4 criteria met)Pathological aortic regurgitation (all 4 criteria met)
Seen in at least 2 viewsSeen in at least 2 views
Jet length ≥2 cm in at least 1 viewJet length ≥1 cm in at least 1 view
Peak velocity >3 m/sPeak velocity >3 m/s
Pansystolic jet in at least 1 envelopePan diastolic jet in at least 1 envelope

Loading conditions should be accounted for at time of echocardiography/Doppler assessment.

Table 4 morphology, and reading the jet
  • Acute mitral valve changes: Annular dilation; Chordal elongation; Chordal rupture resulting in flail leaflet with severe mitral regurgitation; Anterior (or less commonly posterior) leaflet tip prolapse; Beading/nodularity of leaflet tips.
  • Chronic mitral valve changes (not seen in acute carditis): Leaflet thickening; Chordal thickening and fusion; Restricted leaflet motion; Calcification.
  • Aortic valve changes in either acute or chronic carditis: Irregular or focal leaflet thickening; Coaptation defect; Restricted leaflet motion; Leaflet prolapse.
  • On occasion, particularly early in ARF, morphology may be normal while Doppler shows regurgitation as defined in Table 3. These findings can also be seen in chronic rheumatic heart disease.
  • Jet length, velocity and completeness of the Doppler envelope are influenced by the systemic blood pressure. It is reasonable, whenever circumstances allow, to measure BP at the echo, and to include BP data when serial echocardiograms are performed, for the comparison.
  • Signals that are not holosystolic and peak velocity <3.0 m/s are more likely physiological than pathological.
  • In valvulitis only the coapting portion of the anterior leaflet tip prolapses, without billowing of the body, and the jet is typically posterolateral. Isolated aortic regurgitation is rarely the sole valvular finding.
Table 6: differential diagnosis, as printed
  • Arthritis: Septic arthritis (including gonococcal); Connective tissue and other autoimmune diseases such as juvenile idiopathic arthritis; Viral arthropathy; Reactive arthropathy; Lyme disease; Sickle cell anemia; Infective endocarditis; Leukemia or lymphoma; Gout and pseudo gout; Poststreptococcal reactive arthritis; Henoch-Schonlein purpura.
  • Carditis: Physiological mitral regurgitation; Mitral valve prolapse; Myxomatous mitral valve; Fibroelastoma; Congenital mitral valve disease; Congenital aortic valve disease; Infective endocarditis; Cardiomyopathy; Myocarditis, viral or idiopathic; Kawasaki disease.
  • Chorea: Drug intoxication; Wilson disease; Tic disorder; Choreoathetoid cerebral palsy; Encephalitis; Familial chorea (including Huntington disease); Intracranial tumor; Lyme disease; Hormonal; Metabolic (eg, Lesch-Nyhan, hyperalaninemia, ataxia telangiectasia); Antiphospholipid antibody syndrome; Autoimmune: Systemic lupus erythematosus, systemic vasculitis; Sarcoidosis; Hyperthyroidism.

Recurrence and "possible" rheumatic fever

ClassRecommendationLOE
IIbReliable past history of ARF or established RHD, documented GAS infection: the recurrent row may be sufficient for a presumptive diagnosis.C
IMinor manifestations alone: exclude other more likely causes first.C
IIa"Possible" ARF, genuine uncertainty: reasonable to consider offering 12 months of secondary prophylaxis, then reevaluate with history, examination and repeat echo.C
Exceptions to GAS evidence, and when "possible" applies
  • Chorea may be the only manifestation at presentation. Evidence of recent GAS infection may be difficult or impossible to document because of the long latent period. Worsening movements in a child with residual chorea may be hard to tell from a new attack.
  • Chronic, indolent rheumatic carditis (rare), with insidious onset and slow progression: no identifiable history of ARF; previously undetected subclinical carditis; cardiovascular sequelae presenting remote from the initial episode. The statement names it as an exception and gives no count.
  • Endemic skin or upper respiratory GAS infection: a negative antibody test helps exclude recent infection; a positive test does not necessarily mean infection in the past few months.
  • "Possible" rheumatic fever: the criteria are not fulfilled but there is good reason to suspect ARF, for example in high-incidence settings where acute phase reactants or streptococcal tests are not available, documentation is not clear, or the history is unreliable.
The other class and LOE rows
ClassRecommendation (Gewitz 2015, paraphrased)LOE
IIaReasonable to consider individuals low risk if they come from a setting or population known to have low rates of ARF or RHD.C
IIaWith reliable epidemiological data, reasonable to define low risk as ARF incidence <2 per 100 000 school-aged children (usually 5–14 years old) per year or all-age RHD prevalence ≤1 per 1000 population per year.C
IChildren not clearly from a low-risk population are at moderate to high risk depending on their reference population.C
IEcho with Doppler in all confirmed and suspected ARF.B
IIaReasonable to consider serial echo/Doppler in any patient with diagnosed or suspected ARF, even without documented carditis at diagnosis.C
IEcho/Doppler, strictly applying the findings, to assess for carditis without auscultatory findings, particularly in moderate- to high-risk populations and when ARF is considered likely.B
IEcho/Doppler findings not consistent with carditis should exclude it in a patient with a murmur otherwise thought to indicate rheumatic carditis.B
IConsider monoarthritis part of the ARF spectrum only in moderate- to high-risk populations.C
IIbPolyarthralgia as a major manifestation: only for moderate- or high-incidence populations, after careful consideration and exclusion of other causes such as autoimmune, viral or reactive arthropathies.C
IEach of the three streptococcal evidence rows in the checklist.B
IIaRecurrent symptoms (particularly joints) despite adherent prophylaxis, no serological evidence of GAS infection and no echo evidence of valvulitis: reasonable to conclude they are not likely ARF; stopping prophylaxis may be appropriate.C
The Figure as a table: diagnosis strategy, Panels A–D

Adapted from Gewitz 2015, Figure, as corrected in 2020. Printed note: B, C, and D require evidence of GAS infection. *Subclinical carditis can be considered.

PanelPathBox
A. Chorea"Clinical" (our reading: clinical carditis): YesARF diagnosed
A. Chorea"Clinical": No; Echo Doppler Subclinical carditis: YesARF diagnosed
A. Chorea"Clinical": No; Echo Doppler Subclinical carditis: No; Rule out all elseARF diagnosed
B. ArthritisClinical carditis or subclinical (echo Doppler)ARF diagnosed
B. ArthritisNo carditis (neg echo Doppler); 2 minor criteria or another major criterionARF diagnosed
B. ArthritisNo carditis (neg echo Doppler); No criteriaAlt Diagnosis
C. Clinical CarditisEcho confirms; One minor onlyProbable ARF. Repeat echo at 14-21 days
C. Clinical CarditisEcho confirms; Another major criterion or 2 minor criteriaARF diagnosed
C. Clinical CarditisNegative EchoAlternate diagnosis
D. Subcutaneous Nodules Or Erythema MarginatumOther major* or 2 minorARF diagnosed
D. Subcutaneous Nodules Or Erythema MarginatumNo major and /or 1 minorConsider alternative diagnosis

Secondary prophylaxis (AHA 2009)

Tables 3 and 4, as printed in Gerber 2009 (endorsed by the AAP).

Agent and dose (Table 4)
ClassAgent, dose, modeLOE
IBenzathine penicillin G, intramuscular: 600 000 U for children ≤27 kg (60 lb), 1 200 000 U for those >27 kg (60 lb) every 4 wk†A
IPenicillin V, oral: 250 mg twice dailyB

†Every 3 weeks where incidence is particularly high (Class I, LOE A). United States: only for recurrent ARF despite adherence to every 4 weeks (Class I, LOE C).

Penicillin allergy: sulfadiazine, macrolide or azalide (Table 4)

Sulfonamides are contraindicated in late pregnancy. Macrolides, and to a much lesser extent azalides, can prolong the QT interval. Macrolides should not be taken with inhibitors of cytochrome P-450 3A (Gerber 2009, p. 1548).

ClassAgent, dose, modeLOE
IPenicillin allergy: sulfadiazine, oral: 0.5 g once daily for patients ≤27 kg (60 lb), 1.0 g once daily for patients >27 kg (60 lb)B
IAllergic to penicillin and sulfadiazine: macrolide or azalide, oral. Dose printed as "Variable".C

Gerber 2009, p. 1548: sulfisoxazole is acceptable at the same dose (Class IIa, LOE C). Allergic to both penicillin and sulfisoxazole: erythromycin or clarithromycin, or azithromycin (Class I, LOE C). "There are no published data about the use of other penicillins, macrolides, azalides, or cephalosporins for the secondary prevention of rheumatic fever." Table 4 words the last row as penicillin and sulfadiazine.

Duration after last attack (Table 3)
ClassCategory and durationLOE
IRheumatic fever with carditis and residual heart disease (persistent valvular disease*): 10 years or until 40 years of age (whichever is longer), sometimes lifelong prophylaxisC
IRheumatic fever with carditis but no residual heart disease (no valvular disease*): 10 years or until 21 years of age (whichever is longer)C
IRheumatic fever without carditis: 5 years or until 21 years of age (whichever is longer)C

*Clinical or echocardiographic evidence.

Severe RHD (AHA 2022 advisory). Severe aortic insufficiency, severe mitral stenosis, severe aortic stenosis, Ventricular dysfunction (EF <50%) or Severe symptoms (NYHA class III or IV): oral prophylaxis, if reliably available and affordable, should be strongly considered (preferably penicillin, unless contraindicated). Oral is "unequivocally inferior", and this departs from AHA 2009's text. WHO 2024: may be considered. Available evidence and expert opinion; not split by age. Severity by the ACC/AHA classification Adult

Starting, stopping, giving the injection
  • Starting. Continuous prophylaxis for well-documented histories of rheumatic fever, including cases manifested solely by Sydenham chorea, and for definite evidence of RHD (Class I, LOE A), started as soon as ARF or RHD is diagnosed. In acute rheumatic fever, a full therapeutic course of penicillin is first given to eradicate residual GAS, even if the throat culture is negative (Gerber 2009, Table 2, not reproduced here).
  • Stopping. Persistent valvular disease: after that duration, the severity of the valvular disease and the potential for exposure to GAS should be discussed, and continued prophylaxis (potentially lifelong) considered for high-risk patients. Prophylaxis continues after valve surgery, including prosthetic valve replacement. Stopping or reinstating follows discussion with the patient of the potential risks and benefits, and careful consideration of the epidemiological risk factors (Gerber 2009, p. 1547).
  • Doses. Gerber 2009's text gives "1 200 000 U" with no weight; its Table 4 splits at 27 kg. Penicillin V: the dose is for children and adults.
  • Other documents. AHA 2020 lists the same durations in its Table 2; its text words the longest "ARF and severe chronic RHD" and the middle one "ARF and resolved carditis". ACC/AHA 2020 gives the same durations, and 1.2 million U and sulfadiazine 1 g with no weight split, in a guideline for adult patients (Adult). WHO 2024 gives no dose and no general duration, and sends readers to national and professional guidelines. It prefers intramuscular benzathine penicillin (strong recommendation, moderate certainty); oral penicillin is acceptable if an alternative is needed (conditional, moderate certainty). With isolated mild aortic or mitral regurgitation, it says it may be reasonable to discontinue prophylaxis in children with normal echocardiography after 1 to 2 years, citing a trial in latent, screen-detected RHD (Beaton 2022). It does not say whether this applies after ARF.
  • AHA 2009 against AHA 2022. Gerber 2009 (p. 1548): the risk of recurrence is higher on oral prophylaxis; long-acting penicillin is of particular value in those with RHD; oral agents are more appropriate for patients at lower risk. The 2022 advisory takes the other view for its elevated-risk group, because of concern about death from vasovagal compromise after intramuscular injection. It says the evidence is sparse and that there is no direct evidence yet for the mechanism, which it calls highly plausible. Its conclusion words the condition as "if readily available". WHO 2024 (p. 30): oral penicillin "may be considered" in severe valvular heart disease, in particular severe mitral or aortic stenosis or decreased left ventricular systolic function.
  • AHA 2022, other groups. Lower-risk: intramuscular benzathine penicillin unless contraindicated. This includes borderline RHD, mild or moderate valve lesions, asymptomatic severe mitral regurgitation, and postsurgical or interventional RHD with no more than moderate residual valvular heart disease and preserved left ventricular function; isolated severe mitral regurgitation is decided case by case. Risk follows the most severe valve lesion. NYHA symptoms include those from nonstructural factors such as atrial fibrillation and anemia.
  • AHA 2022, giving the injection. If still preferred in the elevated-risk group: a monitored setting with people experienced in cardiopulmonary resuscitation, if possible. For all injections: supine, stay supine at least 5 min and rise slowly, monitor at least 30 min.
  • Our note: the advisory uses the ACC/AHA valve classification because no standardized severity scale for RHD exists. That guideline's focus is adult patients (ACC/AHA 2020, Section 1.4), and the EF and NYHA cut-offs are not paediatric-specific.

The AHA 2015 criteria as printed, with a checklist

Sources and how this page was checked

Sources

How it was checked

Inconsistencies in the sources, as printed

Not used